Interaction of the ACE D Allele and the GNB3 825T Allele in Myocardial Infarction

Christoph K. Naber, Johannes Hüsing, Ulrich Wolfhard, Raimund Erbel, Winfried Siffert

Abstract—In polygenetic disorders, such as ischemic heart disease, the investigation of gene-gene interactions rather than determination of single gene effects is crucial to better understand the contribution of genetic factors. The 825T allele of the G-protein β3-subunit gene (GNB3) associated with enhanced G-protein signaling is a candidate to interact with the angiotensin-converting enzyme (ACE) deletion/insertion (D/I) polymorphism to increase the risk for myocardial infarction (MI). The ACE D/I variant affects the renin-angiotensin system hormones that activate G-protein–coupled receptors. Genotyping at the ACE and GNB3 loci was performed on 585 patients with coronary artery disease with (n=270) or without (n=315) previous MI. Logistic regression analysis demonstrated a significant interaction between the ACE D allele and the GNB3 825T allele (P<0.001). The odds ratio for MI, associated with the 825T allele, was not increased in the presence of the ACE II genotype (OR 0.5; P=0.09) but was significantly higher in 825T allele carriers with the ACE DI genotype (OR 1.9; P=0.01) and further increased in individuals with the ACE DD genotype (OR 2.4; P=0.006). Our data suggest a significant interaction of the GNB3 825T allele with the ACE D allele in MI. These hypothesis-generating data may justify larger prospective studies. (Hypertension. 2000;36:986-989.)

Key Words: myocardial infarction ● genetics ● signal transduction ● G proteins ● angiotensin-converting enzyme

Although coronary artery disease (CAD) and myocardial infarction (MI) are unlikely to be caused by single genetic polymorphisms, few studies have investigated the interaction of susceptibility genes with other genetic or conventional risk factors on MI. Insight into such interactions may result in a significant gain of knowledge about the genetics of the respective genetic background. ACE mediates the conversion of angiotensin I to angiotensin II (AT-II), and, although this has not yet been rigorously proven, it is commonly assumed that the increased serum ACE levels associated with the ACE D allele represent the main mechanism by which the ACE DD genotype increases the risk for MI. AT-II receptors are typical G-protein–coupled receptors; thus it appears plausible to assume that AT-II mediated effects are further enhanced in the presence of an increased responsiveness of G proteins. Enhanced G-protein reactivity is strictly correlated with the 825T allele of the G-protein β3-subunit. The 825T allele is also associated with essential hypertension and with an enhancement of diverse cell functions that may play a role in mechanisms ultimately contributing to an increased risk for MI. Therefore, we investigated the hypothesis that the ACE D allele and the GNB3 825T allele significantly interact to increase the risk for MI. This analysis was conducted within a sample of thoroughly characterized patients with angiographically documented CAD with or without previous MI.

Methods

This study was conducted in accordance with the Helsinki Declaration, revised in 1983.

Study Population

A total of 585 patients with angiographically confirmed CAD were consecutively enrolled in this study. CAD was defined by a luminal narrowing with >50% diameter stenosis in at least 1 coronary artery. The following variables were assessed: current age, gender, body mass index, hypercholesterolemia, hypertension, diabetes, smoking, and previous MI. Previous MI was confirmed in 270 patients according to the American College of Cardiology/American Heart Association guidelines for the management of acute MI, whereas 315 individuals had no previous MI according to standard laboratory, clinical, ECG, and angiographic criteria. Patients were classified as hypertensive when they had a documented history of hypertension, used blood pressure–lowering drugs, or if repeated systolic and diastolic blood pressure measurements were >140/90 mm Hg. Patients were classified as hypercholesterolemic if serum cholesterol values were >5.2 mmol/L or if the individual received cholesterol-lowering drug therapy.

Received February 17, 2000; first decision March 15, 2000; revision accepted June 5, 2000.
From the Abteilung für Kardiologie (C.N., R.E.), Institut für Medizinische Informatik, Biometrie und Epidemiologie (J.H.), Institut für Pharmakologie (W.S.), Abteilung für Thorax- und Kardiovaskuläre Chirurgie (U.W.), Universitätssklinikum Essen (Germany).
Correspondence to Christoph K. Naber, MD, Abteilung für Kardiologie, Universitätsklinikum Essen, Huflandstrasse 55, D-45122 Essen, Germany. E-mail christoph.naber@uni-essen.de
© 2000 American Heart Association, Inc.
Hypertension is available at http://www.hypertensionaha.org
lowering therapy.\textsuperscript{15} Patients were classified having type 2 diabetes when receiving antidiabetic therapy or if fasting glucose was $>6.993$ mmol/L.\textsuperscript{16} All participants were white, of German offspring from the area of Essen, Germany.

**Determination of Genotypes**

Genotyping at the $\text{GNB3}$ and the $\text{ACE}$ gene locus was conducted as previously described.\textsuperscript{5,17}

**Statistical Analysis**

Analyses were carried out with the SAS software package (version 6.1.2). Hardy-Weinberg equilibrium (HWE) was tested by comparing a $\chi^2$ test for continuous variables and by a $\chi^2$ test or, where appropriate, by Fisher’s exact test for dichotomous variables. ORs with 95% CIs were calculated as crude ORs by a likelihood ratio test statistic with a $\chi^2$ distribution with 1 df.\textsuperscript{18} For a preliminary analysis, association for 2 groups was tested by Student’s $t$ test for continuous variables and by a $\chi^2$ test for dichotomous variables. ORs with 95% CIs estimate the relative risk for MI associated with the respective genotypes.\textsuperscript{19} They were calculated as crude ORs by a $\chi^2$ test and by logistic regression analysis including gender, age, body mass index (BMI), hypercholesterolemia, hypertension, type 2-diabetes, and smoking status as established risk factors for MI. Interaction between genotypes at the $\text{ACE}$ locus and $\text{GNB3}$ was estimated within the logistic model. The significance level was set at $\alpha=0.05$.

**Results**

Patients with CAD (with and without MI) and individuals with different genotypes (data not shown) were comparable with respect to common risk factors (Table 1). There was no significant association between genotypes and any of the investigated risk factors. No significant deviation from HWE was observed except for a borderline-significant deviation for the $C825T$ genotypes in the MI group ($P=0.05$), which resulted from a slight lack of homozygous $825T$ allele carriers ($-3\%$; Table 2). The $\text{ACE}$ genotype distribution and $D$ allele frequency were similar in both groups (Table 2), and the OR for MI related to the $\text{ACE} D$ allele was not significantly different from 1.0 (Table 3). The frequency of the $825T$ allele was increased in the group with previous MI ($P=0.03$; Table 2), and logistic regression analysis yielded slightly increased, significant ORs for MI (OR for $TT/TC$, 1.5; 95% CI, 1.1 to 2.0; $P=0.01$) in $825T$ allele carriers (Table 3).

We observed a significant interaction between genotypes at $\text{GNB3}$ and genotypes at the $\text{ACE}$ locus with respect to MI ($P<0.001$). Subsequently, a stratified analysis was performed with respect to $\text{ACE}$ genotypes to study the specific effects of the $\text{GNB3} C825T$ genotypes. $\text{GNB3}$ genotype distribution ($P=0.007$) and $825T$ allele frequency ($P=0.002$) was significantly different between patients with and those without MI within the $\text{ACE} DD$ genotype. A significant albeit smaller effect was still observed within the $\text{ACE} ID$ genotype but not within the $\text{ACE} II$ genotype (Table 2).

Calculation of crude ORs for MI yielded the highest ORs for $TT$ and $TC$ genotypes within the $\text{ACE} DD$ genotype (OR for $TT/CC$, 7.5; 95% CI, 1.5 to 37.3; $P=0.006$; OR for

\begin{table}[h]
\centering
\caption{Demographic Data}
\begin{tabular}{lccccc}
\hline
Phenotype & Sex, & Male/ & Age, y & BMI, kg/m$^2$ & Hypertension, n (%) & Cholesterolemia, n (%) & Type 2 Diabetes, n (%) & Current Smoking, n (%) \\
No MI & n=315 & 248/67 & 62.2±8.4 & 26.6±3.6 & 226 (71.8) & 232 (73.7) & 56 (17.8) & 46 (14.6) \\
MI & n=270 & 228/42 & 60.7±9.4 & 26.6±3.3 & 193 (71.5) & 213 (78.9) & 58 (21.5) & 56 (20.7) \\
P & NS & NS & NS & NS & NS & NS & NS & NS \\
\hline
\end{tabular}
\end{table}

\begin{table}[h]
\centering
\caption{ACE and GNB3 Genotype Distributions in Study Groups}
\begin{tabular}{lcccccc}
\hline
Phenotype/Genotype & TT & TC & CC & P & %T & %C & P \\
\hline
No MI (n=315) & 22 (7.0) & 131 (41.6) & 162 (51.4) & 0.06 & 27.8 & 72.2 & 0.03 \\
MI (n=270) & 23 (8.5) & 135 (50.0) & 112 (41.5) & 33.5 & 66.5 \\
\text{DD} & D & I & II & D & I & P & 0.05 & 0.61 \\
No MI (n=315) & 74 (23.5) & 174 (55.2) & 67 (21.3) & 0.10 & 51.1 & 48.9 & \\
MI (n=270) & 71 (26.3) & 126 (46.7) & 73 (27.0) & 49.6 & 50.4 \\
\text{TT} & TC & CC & P & 0.03 & 0.002 & 0.043 & 0.01 \\
\text{ACE DD} & No MI (n=74) & 2 (2.7) & 27 (36.5) & 45 (60.8) & 0.007 & 20.9 & 79.1 & \text{ACE DI} \\
& MI (n=71) & 9 (12.7) & 35 (49.3) & 27 (38.0) & 37.3 & 62.7 & 0.021 & 27.6 & 72.4 & 0.043 \\
\text{ACE II} & No MI (n=174) & 14 (8.0) & 68 (39.1) & 92 (52.9) & 35.3 & 64.7 & 0.20 & 35.8 & 64.2 & 0.10 \\
& MI (n=126) & 10 (7.9) & 69 (54.8) & 47 (37.7) & \\
\hline
%T, %C, %D, %I indicate frequency of the respective allele (%).
\end{tabular}
\end{table}

Values are n (%) or %.
TABLE 3. Odds Ratios for MI for ACE and GNB3 Genotypes

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE DD vs II</td>
<td>1.1</td>
<td>0.8–1.7</td>
<td>0.29</td>
</tr>
<tr>
<td>GNB3 TT/TC vs CC</td>
<td>1.5</td>
<td>1.1–2.0</td>
<td>0.01</td>
</tr>
</tbody>
</table>

**Discussion**

**ACE D Allele and Risk for MI**

In this study, as in others, the OR for MI related to the ACE D allele was not increased. It is noteworthy that the first report on an association between the ACE DD genotype and MI in the ECTIM study showed no differences concerning the distribution of ACE genotypes between cases and control subjects, except in those at low risk for MI. A recent meta-analysis, however, supports an association of the ACE D allele with MI in whites, which appears stronger in the Japanese.

**GNB3 825T Allele and Risk for MI**

Several characteristics of 825T allele carriers make a contribution to MI of this variant sensible: (1) the 825T allele was shown to be associated with hypertension and obesity, 825 allele at GNB3. G-protein-coupled receptors, whose signaling properties may be altered in the presence of an 825T allele at GNB3. G-protein βγ-subunits play a role in modulating agonist-receptor affinity of the AT-II receptors, 28 and AT-II in particular increases the expression of PTX-sensitive G proteins, 29 whose signaling properties are in turn enhanced in the presence of an 825T allele at GNB3. In addition, several pathways downstream of the AT-II receptors affect signaling cascades in which G protein βγ-subunits are assumed to be involved, for example, activation of phospholipases C and D, regulation of Ca channels, 32 and the transactivation of growth factors. 33 For example, such an interaction may result in a further enhanced platelet aggregation 31,34 with an increased susceptibility for acute coronary thrombosis. Unfortunately, little is known about the specific contribution of Gβ3 and its splice variant, Gβ3s, to these processes. Moreover, besides increased ACE levels, an effect of the ACE D allele on AT-II concentration has not yet been proven. In addition, our study sample comprised only individuals with nonfatal MI, a problem of

825T allele and the ACE D allele. To study the specific effects of the GNB3 C825T genotypes, subsequent stratification was performed with respect to the ACE genotypes. We found a significantly increased OR for MI associated with the 825T allele in individuals with the ACE DD genotype, which was particularly high in GNB3 TT genotypes. The increased OR associated with the 825T allele was smaller in individuals with ACE ID genotype and completely disappeared in conjunction with the ACE II genotype.

These results underline the hypothesis that 2 functional allelic variants, each contributing not or only to a minor extent to a common trait, can interact significantly in combined analyses. The more stringent association of the ACE D allele with MI in Japanese individuals 22 thus may be partly explained by the significantly elevated frequency of the GNB3 825T allele in East Asians compared with whites. 24

On one hand, the observed interaction may result from a synergistic but independent effect of each genetic factor. On the other hand, functional considerations support the hypothesis of a true interaction between both alleles: hormones of the renin-angiotensin system, which is affected by the ACE DI polymorphism, activate G-protein-coupled receptors, whose signaling properties are in turn enhanced in the presence of an 825T allele at GNB3. In addition, several pathways downstream of the AT-II receptors affect signaling cascades in which G protein βγ-subunits are assumed to be involved, for example, activation of phospholipases C and D, regulation of Ca channels, and the transactivation of growth factors. For example, such an interaction may result in a further enhanced platelet aggregation with an increased susceptibility for acute coronary thrombosis. Unfortunately, little is known about the specific contribution of Gβ3 and its splice variant, Gβ3s, to these processes. Moreover, besides increased ACE levels, an effect of the ACE D allele on AT-II concentration has not yet been proven. Thus, the molecular nature of the interaction of the GNB3 825T allele with the ACE D allele remains to be elucidated.

Some additional limitations of the present study should be mentioned: We confined our analysis to patients with CAD. As a result, CAD as the major risk factor for MI and other risk factors are evenly distributed in the groups with and without MI and on different genotypes. Because such a selection might cause a specific bias, future studies will have to involve healthy subjects as well. In addition, our study sample comprised only individuals with nonfatal MI, a problem of
several comparable genetic association studies. Hence, inherent to study design, our results do not unequivocally rule out a survival advantage for 825T allele carriers in acute MI. In conclusion, our data suggest a significant interaction and combined contribution of the GNB3 825T allele and the ACE D allele to MI. More investigations into gene-gene interactions is a prerequisite before the implementation of genetic testing into clinical routine diagnostics, as the reproducibility and predictive power is still far too low. The decoding of the entire human genome is soon to come, and novel techniques for assessing sequence variation on a genome scale will prompt comprehensive studies of comparative genomic diversity in human populations. Consequent research in the field of gene-gene and gene-environment interactions will be required to develop diagnostic scores that more precisely predict the individual risk for multifactorial disorders such as MI.

Acknowledgment
This study was supported by the Deutsche Forschungsgemeinschaft (DFG SI 393/12-2).

References


Interaction of the ACE D Allele and the GNB3 825T Allele in Myocardial Infarction
Christoph K. Naber, Johannes Hüsing, Ulrich Wolfhard, Raimund Erbel and Winfried Siffert

Hypertension. 2000;36:986-989
doi: 10.1161/01.HYP.36.6.986

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/36/6/986

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/